School
School of Pharmacy
Department
Pharmacy Practice
Office Location
40 Foster 234
Worcester
Office Phone Office Phone: 508.373.5747
About
Dr. Timothy Aungst, PharmD, is a professor of pharmacy practice at MCPHS and a clinical pharmacist specializing in the intersection of digital health and patient care. Over the past decade, he has established himself as a leading expert in integrating smart medications, digital therapeutics, digital medicines, remote patient monitoring, and the digitalization of patient care.
Dr. Aungst has served in numerous advisory roles within the digital health sector, contributing to clinical decision-making frameworks and payor coverage strategies. He currently advises the Digital Therapeutics Alliance and collaborates with the Digital Medicine Society, the American Pharmacist Association, and the American Association of Colleges of Pharmacy to develop digital health care standards and educational resources. His work includes creating training modules and certification programs to prepare the pharmacy profession for the evolving landscape of digital health care.
Education
- Doctorate of Pharmacy, Wilkes University Nesbitt School of Pharmacy
- PGY-1 Pharmacy Practice Residency , St. Luke's University Hospital
Research Interests
- Digital Health Technologies
- Digital Therapeutics
- Digital Medicine
- Artificial Intelligence
- Combination Medical Products
Programs
Education
- Doctorate of Pharmacy, Wilkes University Nesbitt School of Pharmacy
- PGY-1 Pharmacy Practice Residency , St. Luke's University Hospital
Research Interests
- Digital Health Technologies
- Digital Therapeutics
- Digital Medicine
- Artificial Intelligence
- Combination Medical Products
Programs
Publications
- Wasserman RL, Seger DL, Amato MG, Hwang AY, Fiskio J, Bates DW. A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator. Drug Saf. 2024;47(12):1235-1243.
- Wasserman RL, Edrees HH, Amato MG, Seger DL, Frits ML, Hwang AY, Iannaccone C, Bates DW. Frequency and preventability of adverse drug events in the outpatient setting. BMJ Qual Saf. 2024; Jul 9:bmjqs-2024-017098. doi: 10.1136/bmjqs-2024-017098.
- Bickenbach EM, Keegan CL, Brockel MC, Mast OG, Ghantae A, Hwang AY, Sherrill CH. Changes in Metabolic Parameters of Hemoglobin A1c, Weight, and Blood Pressure During and After COVID-19 Stay-at-Home Orders. J Am Board Fam Med. 2024; jabfm.2023.230205R1.
- Bou-Ghazale L, Oldham E, Bundeff AW, Hwang AY. Evaluation of the change in glycated hemoglobin for patients in an employee health program formerly managed by a pharmacist-run ambulatory care clinic. Am J Health Syst Pharm. 2023;80(21):1564-1569.
- Hayes M, Lynch A, Yoder V, Hwang A, Alderman L, Adewodu T, Baker D. Implementation of pharmacist recommendations in patients with type 2 diabetes enrolled in an employer-sponsored health plan. J Am Pharm Assoc (2003). 2023; 63(4S):S73-S77.
- Sherrill CH, Hwang AY. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020. Ann Pharmacother. 2023; Jun 15:10600280231178886.
- Zhou J, Sherrill CH, Hwang AY, Lee S. Association between mental health and self-care behavior among older adults with diabetes according to Behavioral Risk Factor Surveillance System 2019. Prim Care Diabetes. 2023;S1751-9918(23)00036-0. doi: 10.1016/j.pcd.2023.02.005.
- Bradley CL, McMillin SM, Hwang AY, Sherrill CH. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Ann Pharmacother. 2022; doi:10.1177/10600280221134127.
- Bradley CL, McMillin SM, Hwang AY, Sherrill CH. High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. Ann Pharmacother. 2022;56(8):941-950.
- Hwang AY, Cardel MI, Smith SM. Racial and ethnic differences in blood pressure before and after the 2016 United States general election. Am J Hum Biol 2022;e23785; https://doi.org/10.1002/ajhb.23785.
- Helms MV, Edwards AL, Suszynsky TH, Hwang AY. Prescribing Patterns of Antihypertensive Agents and Blood Pressure Control Among Patients with Incident Stage 2 Hypertension. J Pharm Technol 2022;38(3):142-147.
- Hwang AY, Smith SM. U.S. Trends in Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients with Cardiovascular Disease, 1988-2016. Pharmacotherapy 2021;41:247-256.
- Hwang AY, Dave CV, Smith SM. Use of Prescription Medications that Potentially Interfere with Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension. Am J Hypertens 2018;31(12):1324-1331.
- Hwang AY, Carris NW, Dietrich EA, Gums JG, Smith SM. Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring. Ann Pharmacother 2018;52(11):1085-1090.
- Hwang AY, Gums TH, Gums JG. The benefits of physician-pharmacist collaboration. J Fam Pract. 2017;66(12):E1-E8.
- Hwang AY, Dietrich E, Pepine CJ, Smith SM. Resistant Hypertension: Mechanisms and Treatment. Curr Hypertens Rep. 2017;19(7):56. doi: 10.1007/s11906-017-0754-x.
- Hwang AY, Dave CV, Smith SM. Trends in Antihypertensive Medication Use Among US Patients with Resistant Hypertension, 2008 to 2014. Hypertension 2016;68:1349-1354.
- Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Pharmacotherapy 2017;37(2):236-248.
- Carris NW, Hwang AY, Smith SM, Taylor JR, Sando K, Powell J, Rosenberg EI, Zumberg MS, Gums JG, Dietrich EA, Vogel Anderson K. Anticoagulation-related satisfaction associated with extended-interval warfarin monitoring: A pre-specified analysis of the FADE-OUT study. J Thromb Thrombolysis 2016;42(4):486-493.
- Hwang AY, Gums JG. The emergence and evolution of antimicrobial resistance: Impact on a global scale. Bioorg Med Chem 2016;24(4):6440-6445.
Awards & Honors
- Pharmacy Faculty Preceptor of the Year 2016-2017
- Cardinal Award 2024
- Advisor of the Year 2015